AbbVie ABBV stock has gained 16.1% so far this year compared with an increase of 4.0% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below.

Biotech stocks toppled late Wednesday after Trump announced broad global tariffs, including a 20% tariff on goods from Europe ...

The general mood among these heavyweight investors is divided, with 43% leaning bullish and 21% bearish. Among these notable ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Shares of AbbVie Inc. ABBV slid 1.55% to $206.27 Tuesday, on what proved to be an all-around mixed trading session for the ...

AbbVie is grappling with diminishing Humira sales and is also trading at an above-average P/E. See why I rate ABBV stock as a ...

Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more ...

Genmab denies the accusation that it knowingly stole confidential information in a $1.8 billion deal to acquire a cancer drug ...

As AbbVie accuses Genmab of unlawfully using proprietary ADC technology, find out about their collaboration and the dispute ...

Some of the country's largest drugmakers could be impacted by President Donald Trump's reciprocal tariffs, announced on ...

Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have received an average recommendation of “Moderate Buy” from the twenty ...

Shares of AbbVie were recently trading for $212 apiece, and the company's total annual dividend amount (paid out over four ...